Uveitis in Giant Cell Arteritis: A Retrospective Study of Seven Observational Cases and Literature Review

Ocul Immunol Inflamm. 2024 Oct;32(8):1844-1851. doi: 10.1080/09273948.2023.2264383. Epub 2023 Oct 10.

Abstract

Purpose: To describe the demographic and clinical characteristics of uveitis in patients with giant cell arteritis (GCA), their treatments, and evolution.

Methods: A national retrospective cohort study was performed. The inclusion criteria were as follows: patients with GCA fulfilling the 2022 ACR/EULAR criteria and a diagnostic of uveitis attested by an ophthalmologist.

Results: Seven women were included. The median age at diagnosis of uveitis was 71 years (64-84). All uveitis were diagnosed during active GCA (five at initial diagnosis, two at relapse). All uveitis were acute (100%), mostly anterior (86%) and bilateral (71%). Granulomatous features were less common (29%). All uveitis were treated with local and systemic corticosteroids. After a median follow-up of 30 (21-55) months, all patients achieved complete ophthalmic remission, with only one relapse at 2 years. GCA was also in complete remission.

Conclusions: Uveitis could reveal GCA, and its presence correlated with disease activity of GCA. The most frequent clinical presentation of uveitis was acute and anterior; using local and systemic corticosteroids, the prognosis was favorable.

Keywords: Giant cell arteritis; elderly; uveitis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Follow-Up Studies
  • Giant Cell Arteritis* / complications
  • Giant Cell Arteritis* / diagnosis
  • Giant Cell Arteritis* / drug therapy
  • Glucocorticoids* / therapeutic use
  • Humans
  • Middle Aged
  • Retrospective Studies
  • Uveitis* / diagnosis
  • Uveitis* / drug therapy
  • Uveitis* / etiology
  • Visual Acuity / physiology

Substances

  • Glucocorticoids